Cost-effectiveness of testing for breast cancer susceptibility genes.

@article{Holland2009CosteffectivenessOT,
  title={Cost-effectiveness of testing for breast cancer susceptibility genes.},
  author={Margaret L. Holland and Alissa J. Huston and Katia K. Noyes},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2009},
  volume={12 2},
  pages={207-16}
}
OBJECTIVES Genetic mutations in breast cancer susceptibility genes BRCA1/2 are associated with an increased risk of breast/ovarian cancers. Cost-effective preventive measures are available for women who test positive. The objective of this study was to determine at what risk of mutation it is cost-effective to test women for BRCA1/2 mutations. METHODS A semi-Markov model accrued costs and quality-adjusted life years (QALYs) annually from the societal perspective. The estimates of health-care… CONTINUE READING